Gammon Infrastructure Projects Ltd said its special purpose vehicle (SPV), Punjab Biomass Power Ltd has started its first biomass based plant of 12 MW at Patiala and is exporting power to the state grid.
The plant in which the company has 50% stake has been designed to use biomass fuel such as rice straw or husk and has sufficient stocks of fuel to operate till the next harvesting season, beginning from September, it informed Bombay Stock Exchange (BSE).
The SPV has entered a 20 years power purchase agreement (PPA) with Punjab State Electricity Board. As per the PPA, the current tariff for sale of power is Rs4.24 per unit of power.
On Thursday, Gammon Infra shares ended 2% higher at Rs28 on the BSE, while the benchmark Sensex closed 0.9% up at 17,616 points.
Reliance Power Ltd said its second unit of Rosa Power plant started producing power and the same has been synchronised with the Uttar Pradesh state grid.
The Mumbai-based company's first unit of 300 MW of the project was synchronised to the grid on 28 December 2009. Rosa Power Supply Co, the unit of Reliance Power is setting up 1,200 MW project in Shahjahanpur district of Uttar Pradesh, it said in a filling to the Bombay Stock Exchange (BSE).
On Thursday, Reliance Power shares ended 0.7% up at Rs175 on the BSE, while the benchmark Sensex closed 0.88% up at 17,616 points.
Mumbai-based Sun Pharma Ltd said it received an abbreviated new drug application (ANDA) approval from US Food and Drug Administration (USFDA) to market its levetiracetam injection which is generic version of Keppra injection,.
This levetiracetam injection 100 mg/ml packaged in 500 mg/5ml single use vials is equivalent to UCB's Keppra injection 100 mg/ml. Annual sale in the US for levetiracetam injection is estimated at $85 million, Sun Pharma said in a regulatory filing.
Levetiracetam injection is used in adjunctive therapy for the treatment of partial onset seizures in adults with epilepsy. This injection is an alternative for patients when oral administration is temporarily not feasible.
On Thursday, Sun Pharma shares ended 0.6% down at Rs1,690 on the Bombay Stock Exchange, while the benchmark Sensex closed 0.88% up at 17,616 points.